Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | AHR | P35869 | 3/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | PRKCI | P41743 | 2/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TAF1 | P21675 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | F7 | P08709 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30122523 | 1.00 | DYRK1A (0.48) | DYRK1AAHRTNFRIPK1GRM5 | |
| SCHEMBL23233865 | 0.76 | GRM5 (0.41) | DYRK1AAHRTNFRIPK1GRM5 | |
| SCHEMBL9942590 | 0.76 | AHR (0.43) | DYRK1AAHRTNFRIPK1GRM5 | |
| SCHEMBL652414 | 0.74 | GRM5 (0.40) | DYRK1AAHRTNFRIPK1GRM5 | |
| SCHEMBL1154874 | 0.74 | GRM5 (0.43) | DYRK1AAHRTNFRIPK1GRM5 | |
| SCHEMBL30678614 | 0.74 | GRM5 (0.43) | DYRK1AAHRTNFRIPK1GRM5 | |
| SCHEMBL2633337 | 0.74 | GRM5 (0.43) | DYRK1AAHRTNFRIPK1GRM5 | |
| SCHEMBL401223 | 0.74 | NOS3 (0.42) | AHRTNFRIPK1GRM5AXL | |
| SCHEMBL30781502 | 0.74 | TNF (0.44) | DYRK1AAHRTNFRIPK1GRM5 | |
| SCHEMBL15367016 | 0.74 | CCR8 (0.57) | DYRK1AAXLPRKCIRXFP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118046636-A | Environment-friendly metal surface modified polyurethane sandwich panel | 山东北理华海复合材料有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-104093715-B | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives | 埃科特莱茵药品有限公司 | 2017-04-26 | — | — | CN | claimed |
| EP-4103559-B1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20250049812-A1 | Compounds that Inhibit Necroptosis and Their Preparation Methods | SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) | 2025-02-13 | — | — | US | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-118046636-A | Environment-friendly metal surface modified polyurethane sandwich panel | 山东北理华海复合材料有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20030069266-A1 | Aids therapy | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| CN-1404392-A | Antiviral azaindole derivatives | BRISTOL MYERS SQUIBB CO (US) | 2003-03-19 | — | — | CN | disclosed |
| EP-1257276-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6476034-B2 | AIDS THERAPY | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| WO-2002085301-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020119982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-08-29 | — | — | US | disclosed |
| WO-2002062423-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020061892-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
| WO-2001062255-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | DYRK1A 3956/4885AHR 1997/4885TNF 3388/4885 |
| US-20020061892-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | DYRK1A 3956/4885AHR 1997/4885TNF 3388/4885 |
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | PADI6, PADI4, PADI1 | DYRK1A 1247/4885AHR 2613/4885TNF 3108/4885 |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | DYRK1A 1187/4885AHR 195/4885TNF 4327/4885 |
| US-20030069266-A1 | Aids therapy | ENTPD5, CCR5, ITPA | DYRK1A 4700/4885AHR 1309/4885TNF 250/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | DYRK1A 4646/4885AHR 1838/4885TNF 3246/4885 |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | DYRK1A 1187/4885AHR 195/4885TNF 4327/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | DYRK1A 937/4885AHR 174/4885TNF 4478/4885 |
| US-20250049812-A1 | Compounds that Inhibit Necroptosis and Their Preparation Methods | RIPK1, RIPK3, RIPK4 | DYRK1A 1418/4885AHR 4464/4885TNF 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.